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Abstract
Background: Up to half a billion human clinical cases of malaria are reported each year, resulting
in about 2.7 million deaths, most of which occur in sub-Saharan Africa. Due to the over-and misuse
of anti-malarials, widespread resistance to all the known drugs is increasing at an alarming rate.
Rational methods to select new drug target proteins and lead compounds are urgently needed. The
Discovery system provides data mining functionality on extensive annotations of five malaria
species together with the human and mosquito hosts, enabling the selection of new targets based
on multiple protein and ligand properties.
Methods: A web-based system was developed where researchers are able to mine information
on malaria proteins and predicted ligands, as well as perform comparisons to the human and
mosquito host characteristics. Protein features used include: domains, motifs, EC numbers, GO
terms, orthologs, protein-protein interactions, protein-ligand interactions and host-pathogen
interactions among others. Searching by chemical structure is also available.
Results: An in silico system for the selection of putative drug targets and lead compounds is
presented, together with an example study on the bifunctional DHFR-TS from Plasmodium
falciparum.
Conclusion: The Discovery system allows for the identification of putative drug targets and lead
compounds in Plasmodium species based on the filtering of protein and chemical properties.
Background
Even after a century of attempts to control and eradicate
malaria, up to half a billion clinical cases are reported
each year [1] with an annual death rate of 2.7 million [2].
One of the most studied pathogens of all time, the para-
site Plasmodium falciparum accounts for 80% of clinical
cases and 90% of deaths from malaria [3]. Malaria is a
complicated, but curable and preventable disease. Mil-
lions of lives can be saved if the disease is detected early
and adequately treated. As P. falciparum is becoming
increasingly resistant to current anti-malarial drugs and
the development of a vaccine is an extremely time-con-
suming, ongoing process, the death rate is expected to
double in the next 20 years [4]. Since malaria drug
research is not economically feasible for international
pharmaceutical companies, the responsibility to ease the
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burden of malaria falls upon the shoulders of third world
countries.
A major limitation in malaria research is the availability of
effective approaches to mine post-genomic data for new
putative drug targets and lead compounds. The selection
criteria for promising drug targets are therefore of extreme
importance to researchers involved in malaria target
screening projects and lead design [5,6]. Currently, the
main available sources of protein annotation and interac-
tion data specifically relevant to malaria include Plas-
moDB [7,8], PlasmoMap [9,10], the Malaria Drug Targets
database [11], the TDR Targets Database [12,13] and the
Plasmodium falciparum Interactome Database [14].
Although PlasmoDB is a comprehensive annotation data-
base, the focus of the search environment is not specifi-
cally directed towards the drug target and lead discovery
process, and protein-ligand interactions are not provided.
The MDT database does provide some information on
potential drug targets and their inhibitors. PlasmoMap
allows protein-protein interaction data from predictions
to be downloaded, a single PlasmoDB ID may also be
queried for predicted interactions, but no advanced
searches against the data are offered. The TDR Targets
database serves as an information repository as well as a
tool for the prioritization of targets in whole genomes
against neglected tropical diseases including malaria.
PlasmoID is a developing project that provides protein
interactions for P. falciparum, but the main aim of the
project is to build metabolic pathways using protein-pro-
tein interactions. A brief summary of key features of these
resources is provided in Table 1.
No tool exists to perform advanced interactive mining of
protein together with ligand properties in a species-com-
parative environment. The Discovery project attempts to
provide an interface where researchers may efficiently per-
form the selection of putative drug targets and lead com-
pounds based on relevant properties. Relationships were
constructed between the proteins, protein features and
chemical compounds in a way that allows powerful
searching and efficient navigation between molecules.
Methods
Discovery was developed in Python using the TurboGears
web development framework [15] with an underlying
MySQL database [16]. Protein sequences for P. falciparum,
Plasmodium vivax,  Plasmodium chabaudi,  Plasmodium
berghei and Plasmodium yoelii were obtained from Plas-
moDB and for Homo sapiens and Anopheles gambiae from
Ensembl [17]. Data for ligand-protein interactions were
collected from DrugBank [18], KEGG [19] and PDB-Lig-
and [20] and protein-protein interaction data from MINT
[21] and DIP [22]. Currently, only hits common to both
MINT and DIP are displayed, with a MINT cut-off value of
0.3. Blast searches against PDB-Ligand and DrugBank
were performed using NCBI BLAST with an E-value cut-off
of 1.0e-6. InterPro [23] analysis was performed using the
latest InterProScan [24] from the EBI. Homology models
of P. falciparum and human proteins were obtained from
ModBase [25]. Custom ortholog clusters were generated
with OrthoMCL [26]. An outline of the structure of the
Discovery system is provided in Figure 1. Chemical
searches, displays and ADMET calculations were imple-
mented using the Marvin applet and JChem Base from
ChemAxon [27]. Jmol [28] was used to display the 3D
structures and Jalview [29] to display the T-Coffee [30]
alignments of the OrthoMCL clusters.
The power of the Discovery system is in the rich relations
between the different data types in the system. Relations
to protein features were created based on existing annota-
tions, or analyses performed in-house. Inter-and intra-
species protein-protein interaction predictions were based
on orthology to interacting partners in DIP and MINT.
Predicted protein-ligand interactions were based on
Table 1: The availability of some key features in malaria web resources relevant to drug target and lead identification.
Discovery PlasmoDB PlasmoMap MDT TDR PlasmoID
Orthology ✓✓ ✗ ✗ ✓ ✗
Functional Annotation ✓✓ ✗ ✓ ✓ ✓
Metabolism ✓✓ ✗ ✗ ✓ ✗
Structure ✓✓ ✗ ✓ ✓ ✗
Protein Interactions ✓✓ ✓ ✗ ✗ ✓
Druggability ✗✗ ✗ ✗ ✓ ✗
Ligand Interactions ✓✗ ✗ ✗ ✓ ✗
Host/pathogen ✓✗ ✗ ✗ ✗ ✗
Expression ✗* ✓✗ ✗ ✓ ✗
Chemo-informatics ✓✗ ✗ ✗ ✗ ✗
Literature ✗* ✓✗ ✓ ✓ ✗
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KEGG annotations and on BLAST searches against PDB
and DrugBank.
Results and discussion
A brief introduction to the resource
The Discovery resource was designed to provide an effec-
tive interface where researchers could view annotations
for malaria proteins that are relevant to the drug design
process, in an environment where comparisons could effi-
ciently be made between organisms. Users may embark
on a search from either a protein or ligand perspective.
When performing a simple search from a protein perspec-
tive, users may enter a PlasmoDB/Ensembl ID or a key-
word. The user is then presented with either the specified
protein, or a list of proteins matching the keyword by
description or by one of its relationships. This list is sepa-
rated by species. The user is then able to further explore
the hits of interest. More powerful is the advanced search
function, where the user may enter search terms in several
categories, and select for the presence or absence of spe-
cific relations (Figure 2). The results are returned as above.
When exploring the data for a selected protein, the user is
presented with a tabbed environment with different cate-
gories of data (Figure 3). The first tab shows a summary of
the protein's GO and EC terms, a graphical summary of
the InterPro features and a view of the protein sequence.
Next is a view of the orthologs and paralogs predicted by
OrthoMCL, together with a Jalview display of the T-Coffee
alignment of these sequences. This is followed by the
InterPro analysis results of the protein sequence, the posi-
tion of the protein in the KEGG metabolic pathway maps
and tertiary structure information such as ModBase mod-
els or BLAST results against PDB. The protein interaction
tab provides results of possible protein-protein interac-
tions based on Y2H studies, PlasmoMAP interactions and
orthology to DIP and MINT interacting partners. The lig-
and interaction tab provides predicted ligand interactions
based on KEGG annotations and BLAST results against
PDB and DrugBank. Host-pathogen interaction predic-
tions are based on orthology to MINT and DIP interacting
partners, with species filtering.
When approaching the search from the ligand perspective,
the user may search by ligand keyword, or by drawing a
chemical structure using the Marvin applet. Different
methods are then available to search with the structure
against ligands from KEGG, PDB and DrugBank using the
ChemAxon JChem Base functionality. Results are dis-
played as a JChem table, and the user may select a com-
pound to view further information. A view is then
provided of the compound's structure, ADMET properties
as pre-calculated in JChem Base and possible interacting
proteins based on KEGG annotations, and BLAST results
against PDB and DrugBank (Figure 4). The query proc-
esses followed for the different types of searches described
above are summarized in Figure 5.
A sample investigation: P. falciparum DHFR-TS
Dihydrofolate reductase-thymidylate synthase (DHFR-
TS) was selected to demonstrate the data displayed in the
system, as it is well annotated and an established drug tar-
get. DHFR-TS occurs as a bifunctional protein in malaria,
with both the DHFR and TS proteins fused together as a
single polypeptide. Dihydrofolate reductase (DHFR with
PlasmoDB id PFD0830w) is inhibited by the class II anti-
folates, including drugs such as pyrimethamine and pro-
guanil, a prodrug of cycloguanil. All the molecules in the
antifolate drug family currently in use were discovered
during the Second World War in the 1940's, and since
then no new anti-malarial antifolates have been devel-
oped that reached phase I/II clinical trials [31]. One of the
major causes of antifolate resistance is point mutations in
DHFR with a resulting decrease in binding affinity of the
inhibitor to the enzyme. Known inhibitors of P. falci-
parum DHFR include antifolate such as pyrimethamine,
proguanil, aminopterin [32], methotraxate [33], 2-
amino-1,4-dihydro-4,4,7,8-tetramethyl-s-triazino(1,2-a)
benzimidazole and Trp-P-2 [34]. Aminopterin and meth-
otrexate inhibit virtually all DHFR enzymes, including P.
falciparum  and the human DHFR, and although these
drugs cannot be used to treat malaria because of the pos-
sible toxicity of these particular drugs to the human host,
precursors thereof may be used to treat malaria [21]. A
third generation antifolate compound, dihydrotriazene
(WR99210 or BRL 6231) was also recently found to
inhibit P. falciparum DHFR. WR99210 is different from
the resistance-compromized pyrimethamine in that it has
a flexible side-chain that binds tightly with not only the
A represenation of the major protein features displayed in  the Discovery system, together with the sources of informa- tion Figure 1
A represenation of the major protein features dis-
played in the Discovery system, together with the 
sources of information.
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wild-type enzyme, but also the mutant P. falciparum
DHFR, while still retaining anti-malarial activity [35].
Plasmodium falciparum DHFR-TS was selected in the Dis-
covery system by searching with the keyword dihydro-
folate, and selecting the entry 'PFD0830w bifunctional
dihydrofolate reductase-thymidylate synthase'. On the
summary page the EC annotation shows the two enzyme
domains in the protein, EC:1.5.1.3, corresponding to the
dihydrofolate reductase enzymes and EC:2.1.1.45 corre-
sponding to the thymidylate synthases, and links to KEGG
are provided. The GO annotations include GO:0006231
(dTMP biosynthetic process), GO:0006545(glycine bio-
synthetic process), GO:0006730(one-carbon compound
metabolic process), GO:0009165 (nucleotide biosyn-
thetic process), GO:0004146 (dihydrofolate reductase
activity) and GO:0004799 (thymidylate synthase activ-
ity). Orthologs, based on OrthoMCL analysis, are indi-
cated as: A. gambiae AGAP010457-PA with no description,
three human enzymes, namely ENSP00000314727,
ENSP00000314902 and ENSP00000315644, all three of
which are thymidylate synthases, a P. berghei protein
PB000415.02.0 and a P. chabaudi protein PC000873.02.0,
both putative bifunctional dihydrofolate reductase thymi-
dylate synthases. The P. yoelii protein PY04370, a putative
thymidylate synthase, was also returned. It should be
noted here that the ortholog prediction encounters a spe-
cial case with bifunctional proteins, as a protein may only
occur in one OrthoMCL cluster, which in effect groups
bifunctional proteins according to only one of the
domains. In this case, the human and mosquito orthologs
were for the TS domain of the bifunctional enzyme. The
T-Coffee alignment of these proteins is shown in the
JalView applet, enabling further manipulations of the
sequences.
When considering the summary of the InterPro results,
the first featured annotation common to all species is a
BLAST hit (TS) against ProDom, a database of protein
domain families automatically generated from the Uni-
Prot Knowledge Database. Gene3D G3DSA:3.40.430.10
is present in all the Plasmodium species, but not in
human or mosquito. HMMPfam returned two hits as to
be expected for the bifunctional sequence, namely
PF00186, described as DHFR 1, and PF00303 described as
Thymidylat synt.
In human and mosquito, only the TS domain is associated
with this ortholog group, as DHFR and TS occur separately
in these species. HMMPIR hit PIRSF000389 identifies the
The main Discovery interface, allowing ID, keyword, advanced protein property and chemical structure searches Figure 2
The main Discovery interface, allowing ID, keyword, advanced protein property and chemical structure 
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protein as a bifunctional DHFR-TS in all the Plasmodium
species. PatternScan returns two hits, PS00075 and
PS00091, identifying DHFR 1 and thymidylate synthase
in the Plasmodium species, except for P. chabaudi that
does not show the DHFR domain (probably due to the
shorter sequence). Only the TS domain is shown in
human and mosquito. ProfileScan returns ID PS51330,
identifying the Plasmodium proteins as DHFR 2. Super-
family identifies both parts of the bifunctional protein in
the Plasmodium species as SSF55831 (TS) and SSF53597
(DHFR). HMMTigr TIGR03284 (TS) and Gene3D
G3DSA:3.30.572.10 (TS) are present in all species
included. This comparison highlights possible areas that
may be investigated to identify parasite-specific features in
the protein.
Three ModBase models are reported for this protein,
based on DHFR-TS from Leishmania major (PDB template
1qzf), P. falciparum (PDB template 1j3q) and TS from
Pneumocystis carinii (PDB template 1f28). A range of high-
scoring PDB BLAST hits over both DHFR and TS are
returned. PFD0830w is predicted through KEGG annota-
tions and BLAST searches to potentially bind with more
than a hundred ligands, including the well known inhib-
itors of DHFR. When searches were performed using com-
mon chemical compound names or structures such as
pyrimethamine or proguanil, the bifunctional DHFR-TS
from P. falciparum was listed as a possible interacting pro-
tein. No protein-protein or host-pathogen interactions
were predicted for this protein.
The Discovery summary page, showing the tabbed environment for the different result classes Figure 3
The Discovery summary page, showing the tabbed environment for the different result classes.Malaria Journal 2009, 8:178 http://www.malariajournal.com/content/8/1/178
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The Discovery results page for a chemical search, showing the compound properties and protein interaction tab Figure 4
The Discovery results page for a chemical search, showing the compound properties and protein interaction 
tab.
A representation of the different types of searches available in the Discovery system Figure 5
A representation of the different types of searches available in the Discovery system.
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This sample investigation effectively highlights the main
features of DHFR-TS as described in the Discovery system,
including possible orthologs, protein motifs and domains
anda set of ligands possibly interacting with this protein.
Conclusion
The Discovery system currently provides basic and
advanced interfaces to search protein properties in the
resource, as well as a chemical search interface for ligands.
Results include orthology, protein features, metabolic
information, structural information, and interaction
information. Of specific interest is the availability of rela-
tionships between proteins and potential interacting lig-
ands, together with ADMET-related properties for the
ligands. The system currently has some shortcomings such
as the lack of statistical measures for predicted protein-lig-
and and protein-protein interactions. This could be
improved by incorporating sequence conservation across
similar sequences for scoring purposes. Also, the predic-
tion of host-pathogen protein-protein interaction does
not yet take similarity, sub-cellular localization and prop-
erties such as PEXEL motifs and transmembrane regions
into account. Additionally, in the special case of bifunc-
tional proteins, these are currently clustered only with the
ortholog of the best-matching domain by OrthoMCL, and
alternative approaches need to be investigated for bifunc-
tional matching. These and other shortcomings will be
addressed in future releases, yielding futher improve-
ments to the system.
It is anticipated that the Discovery system will offer an
effective starting point where users interested in drug dis-
covery may obtain relevant information about a pre-
selected malaria protein, and discover other proteins of
interest by searching according to a selection of protein
and ligand properties. The system's further development
will serve to make it a valuable tool in the malaria drug
discovery process.
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